At its meeting this week, the PBAC will consider the 'discount rate' but as the national expert advisory body on medicines is not lawfully allowed to provide advice on treatments in the National Medical Stockpile or many of the new therapeutic interventions emerging from company pipelines. What is the real problem? …
This legal quirk of history is a much bigger problem than the 'discount rate'
July 8, 2022 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Australia’s life sciences sector emerges as fast growing, globally connected powerhouse
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
Medicine shortages and workforce gaps threaten the sustainability of Australian care
May 21, 2026 - - Latest News -
Sanofi therapy wins Australian registration for non-relapsing secondary progressive MS
May 20, 2026 - - Latest News -
Owen Smith: 'We are ready to negotiate. We are ready to be a genuine partner'
May 19, 2026 - - Latest News -
Australia bets on translational science to turn discovery into global impact
May 19, 2026 - - Latest News